The Charismatic Charlie Wade

Kobayashi’s Niranex is the flagship product of Kobayashi Pharmaceutical, and most of its revenue and profits are supported by this medicine.

If it is really beaten by Oracle Nova Dias, then Kobayashi Pharmaceutical’s vitality will definitely be greatly injured.

So someone asked Masayoshi Kobayashi: “Mr. Kobayashi, we can’t just wait and die like this! Do you have any good solutions?”

Kobayashi Masayoshi said: “There is also a way to deal with it, that is, we must increase investment in drug research and development, and we must quickly upgrade our current products. If our Niranex can surpass Oracle in terms of efficacy. Stomach, the market must still be ours!”

The person in charge of R&D opened the mouth and said: “My lord, if you want to increase investment in R&D, you need a huge budget. The company was sacked a lot of money some time ago. Can it still afford it now?”

Masayoshi Kobayashi said smoothly: “This is what I’m about to tell you. Our current cash flow is not very good. The investment in the production base in Osaka costs a lot, coupled with the previous accidental losses, which leads us to get it now. The funds invested in research and development are already less than 50 million U.S. dollars, so my idea is to raise a fund as soon as possible, with at least one billion U.S. dollars to upgrade our drug R&D laboratory!”

all sat up straight.

and said, “Before, Chairman Jiro Kobayashi had been negotiating with Mr. Yuhiko Ito, the patriarch of the Ito family, about financing. Surely

Everyone nodded.

Kobayashi has always wanted to take Ito’s investment, and even wanted to become Ito’s son-in-law, otherwise he would not spend

everyone is ready for the marriage between Kobayashi Pharmaceutical and the Ito family. Unfortunately, Jiro Kobayashi disappeared before the marriage

terminated, but they

everyone immediately became interested and asked excitedly: “Sir, I don’t know what kind of valuation the Ito family

family is willing to invest US$4.5 billion in Kobayashi Pharmaceutical at a valuation of US$15 billion, which will account for 30% of Kobayashi’s total shares after the

15 billion

couldn’t help but

Jiro Kobayashi and Ito Yuhiko talked about it, but it was